Molecular Partners Ltd

MOLN

Equity

ISIN CH0256379097 / Valor 25637909

SIX Swiss Exchange (2026-11-02)

CHF 2.78-3.81%

Molecular Partners Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Molecular Partners Ltd is a clinical-stage biopharmaceutical company based in Switzerland, specializing in the development of a novel class of therapeutic proteins known as DARPins (Designed Ankyrin Repeat Proteins). These proteins are engineered to address complex medical conditions, offering potential advantages over traditional antibodies due to their small size, high specificity, and ability to engage multiple targets simultaneously. The company focuses on creating innovative treatments for diseases with significant unmet medical needs, including oncology and infectious diseases. Molecular Partners collaborates with various pharmaceutical companies to advance its pipeline and leverage its proprietary technology platform. Under the leadership of CEO Patrick Amstutz, who co-founded the company in 2004, Molecular Partners has established numerous commercial partnerships and continues to expand its research and development efforts to bring new therapies to market.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-4.14%1Y

-20.6%3Y

-84.5%5Y

Performance

54.7%1Y

63.3%3Y

68.0%5Y

Volatility